RTI International announces promotion
DURHAM — Nicole Barnes has been promoted to vice president of business strategy and communications for RTI International’s International Development Group.
In her new role, Barnes will lead a team to drive client diversification and growth for the group.
Her responsibilities include fostering innovative thinking around business development tasks and approaches, expanding RTI’s client base, assessing competitive trends and communicating the International Development Group’s work worldwide.
Barnes joined RTI in 2003 and most recently served as senior director for business strategy and communications for the International Development Group since 2011.
Since joining RTI, she continued providing advisory services to several governments and also worked extensively on RTI’s strategic positioning and business development.
Barnes has a master’s degree in city planning from the Massachusetts Institute of Technology and a bachelor’s degree in global studies from the University of Iowa.
Pappas joins foundation board
CHARLESTON, S.C. – The Medical University of South Carolina Foundation for Research Development announced that venture capitalist Art Pappas has joined the organization’s board of directors.
Pappas is a managing partner at Durham-based Pappas Ventures, which invests in the life sciences sector and specifically in biotechnology, specialty pharmaceuticals, drug delivery, diagnostics, medical devices and related ventures. He has more than 30 years of experience in the pharmaceutical and life sciences industries.
“I am honored to join the board of directors and look forward to working with FRD and the rest of the board to continue driving health care technologies to market,” Pappas said in a prepared statement.
Before forming Pappas Ventures in 1994, he served as the chief executive for international operations at Glaxo Holdings PLC, which is now known as GlaxoSmithKline. He also has held executive positions at Abbott Laboratories International Ltd. and Merrell Dow Pharmaceuticals.
FRD is the commercialization arm of the Medical University of South Carolina. Its mission is to translate the intellectual property created at MUSC into products and services that benefit the community.
Quintiles announces recognition
DURHAM – The Durham-based biopharmaceutical services company Quintiles announced recently that it was selected as the preferred provider for Phase II/III research among small, mid-size and large biopharmaceutical companies.
The company was selected in Industry Standard Research’s 2014 CRO Quality Benchmarking Phase II/III Service Providers Report.
According to Quintiles, 148 pharmaceutical and biotechnology decision makers were surveyed by ISR for the report, and Quintiles was chosen preferred provider for Phase II/III research among small, mid-size and large biopharmaceutical companies.
“We are delighted once again to be recognized as the industry leader in Phase II/III research,” said Paula Brown Stafford, president of clinical development at Quintiles, in a prepared statement. “This distinction is a result of the work of our tremendous teams around the world and underscores our unique ability to connect insights, expertise and capabilities across our organization to improve the probability of success for our customers.”